Abbott Pinning Tricor Growth On Improved Formulation, Combination Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Company expects the lipid-lowering agent to eventually reach $1 bil. in revenue, almost double the U.S. sales level in 2003. Abbott points to "four strong formulation patents" on the fenofibrate tablet formulation which, it believes, will help keep generics at bay.